Document is current
Any future updates will be listed below
-
Authors
Pasvolsky, Oren
Marcoux, Curtis
Milton, Denái R.
Haider, Asad A.
Tanner, Mark R.
Bashir, Qaiser https://orcid.org/0000-0002-4086-6453
Srour, Samer
Saini, Neeraj
Smallbone, Portia https://orcid.org/0009-0005-5524-5077
Lin, Paul
Ramdial, Jeremy https://orcid.org/0000-0002-8984-3420
Nieto, Yago https://orcid.org/0000-0001-6034-8939
Mohamedi, Ali H.
Siddiqui, Umer R.
Jamil, Abdullah https://orcid.org/0000-0002-4270-751X
Tang, Guilin https://orcid.org/0000-0002-9482-4806
Aljawai, Yosra https://orcid.org/0000-0002-1649-7651
Lee, Hans C.
Patel, Krina K. https://orcid.org/0000-0002-8894-027X
Kebriaei, Partow https://orcid.org/0000-0002-8607-9404
Thomas, Sheeba K. https://orcid.org/0000-0001-8596-7058
Orlowski, Robert Z. https://orcid.org/0000-0002-5723-4129
Champlin, Richard E. https://orcid.org/0000-0002-4314-5037
Shpall, Elizabeth J.
Qazilbash, Muzaffar H. https://orcid.org/0000-0003-2876-2886
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672, P30 CA016672)
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Riney Family Multiple Myeloma Research Fund at MD Anderson from the Paula and Rodger Riney Foundation and the MD Anderson Cancer Center High Risk Multiple Myeloma Moon Shot.
- License Information
-
More Information
Article History
Received: 13 October 2025
Revised: 7 November 2025
Accepted: 14 November 2025
First Online: 5 December 2025
Competing interests
: HCL has received consulting fees from Bristol Myers Squibb, Alexion Pharmaceuticals, Janssen, Regeneron, GlaxoSmithKline, Sanofi, Takeda Pharmaceuticals, Allogene Therapeutics, Pfizer, and Menarini. HCL has also received research funding from Amgen, Bristol Myers Squibb, Janssen, GlaxoSmithKline, Regeneron, Takeda Pharmaceuticals, and Alexion Pharmaceuticals. All other authors report no conflicts of interest.
: This study was approved by the University of Texas MD Anderson Institutional Review Board (IRB) under protocol number PA17-0450. Approval was obtained from the IRB to waive informed consent for this retrospective chart review. The study was conducted in accordance with the Declaration of Helsinki and the 1996 Health Insurance Portability and Accountability Act.
